Becton, Dickinson and Company BDX

BDX Company Overview

Becton, Dickinson and Company (BD), traded on the NYSE under the ticker BDX, is a global medical technology company focused on the development, manufacture, and sale of medical devices, laboratory equipment, diagnostic products, and biosciences tools. The company operates primarily in the healthcare and life sciences industries, serving hospitals, laboratories, physicians, researchers, pharmaceutical companies, and public health agencies. BD’s major revenue drivers include medication delivery systems, diagnostic testing platforms, biosciences instruments, interventional devices, and surgical products. The company is widely recognized for its scale in consumable medical products such as syringes, needles, catheters, infusion systems, and specimen collection technologies.

Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, BD began as an importer of medical supplies and evolved into one of the world’s largest medical technology manufacturers through internal product development and acquisitions. The company expanded significantly through acquisitions including CareFusion in 2015 and C. R. Bard in 2017, which broadened its presence in medication management, infection prevention, vascular care, urology, oncology, and surgical technologies. BD’s strategic positioning is supported by its extensive installed base in healthcare systems, recurring consumables revenue model, global manufacturing footprint, and long-standing relationships with healthcare providers and laboratory networks.